Exopharm Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EX1.AX research report →
Price Chart
About the company
Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo.
- CEO
- Sidney Taubenfeld R.Ph
- IPO
- 2018
- Employees
- 50
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on EX1.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.93M
- P/E
- -0.30
- PEG
- -0.00
- P/S
- 3.13
- P/B
- 0.52
- EV/EBITDA
- -0.23
- Div Yield
- 0.00%
- Gross Margin
- -181.63%
- Op Margin
- -1099.16%
- Net Margin
- -1152.70%
- ROE
- -110.25%
- ROIC
- -73.88%
Latest fiscal year · YoY change
- Revenue
- $618.57K+520.2%
- Gross Profit
- $-1,123,493+72.5%
- Op Income
- $-6,799,039
- Net Income
- $-7,130,264+29.9%
- EPS
- $-0.04+36.7%
- OCF Growth
- +54.4%
- FCF Growth
- +56.8%
- 52W High
- $0.14
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- 1.44
- RSI (14)
- 64
- Avg Volume
- 873.79K
No earnings-call transcripts are available for EX1.AX yet.
- Free Float
- 87.6%
- Shares Outstanding
- 175.77M
- Float Shares
- 154.01M
Our EX1.AX coverage
Recent articles, reports, and earnings notes.
No research on EX1.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EX1.AX report →